TrialAnnals of the rheumatic diseases2015

Certolizumab pegol in rheumatoid arthritis patients with low to moderate activity: the CERTAIN double-blind, randomised, placebo-controlled trial.

J S Smolen et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.